Taiho Oncology, Inc.
Elizabeth Calleja has over 20 years of work experience in the healthcare industry. Elizabeth began their career in 1998 as an Instructor at Memorial Sloan-Kettering Cancer Center, where they worked until 2001. During this time, they also served as a Consultant.
In 2001, Calleja joined Roche as a Clinical Director, a position they held for over 16 years. In this role, they contributed to the development of clinical trials and oversaw medical research projects.
In 2017, Calleja transitioned to Taiho Oncology, Inc. as a Senior Medical Director until 2019. Elizabeth then advanced to the position of Vice President of Clinical Development in January 2020, where they continue to contribute their expertise in clinical research and development.
Throughout their career, Calleja has demonstrated a strong commitment to advancing oncology research and improving patient outcomes.
Elizabeth Calleja attended Georgetown University School of Medicine from 1985 to 1989. Elizabeth obtained their MD degree in the field of Medicine during that time.
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com